slcvl raez #16 treatment options for acquired resistance to egfr tkis: t790m-positive disease
Published 7 years ago • 37 plays • Length 1:57Download video MP4
Download video MP3
Similar videos
-
2:10
slcvl raez #17 treatment options for acquired resistance to egfr tkis: t790m-negative disease
-
2:26
patterns of acquired resistance to egfr tkis in egfr mutation-positive nsclc
-
3:07
third generation egfr tkis for acquired resistance
-
2:33
slcvl raez #12 egfr mutation: what is it, and which patients have it?
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
2:30
acquired resistance to osimertinib in egfr nsclc - 2022 program: targeted therapies forum - english
-
2:43
slcvl raez #14 current standards, leading options for first-line treatment of egfr mutation nsclc
-
2:22
slcvl dr. raez #13 different types of egfr mutations and their potential clinical implications
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
26:27
novel egfr inhibitors in the setting of acquired resistance
-
3:43
how do you help your egfr patients make treatment decisions when their cancers grow?
-
7:48
should avastin be added to egfr tki therapy for egfr mutation-positive nsclc?
-
2:43
post-osimertinib treatment options for egfr nsclc - targeted therapies in lung cancer 2023
-
11:13
gracecast-091_lung-cancer_highlights 2011: the egfr axis
-
4:02
treatment of egfr mutated nsclc - 2022 program: targeted therapies forum - english
-
5:34
gracecastuc-038_lung_managing acq. resistance to egfr therapy (and probably crizotinib, too)
-
18:51
gracecast-140_lung_highlights in lung cancer, 2012: new options for egfr mutation-positive nsclc
-
1:59:57
grace - global resource for advancing cancer education live stream
-
7:35
treatment for patients with egfr nsclc - leading developments & current questions in lung cancer